Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative.
Leon Rapoport B, Garcia-Morillo M, Font C, Samoon Z, Jabbar AA, Kourie HR, Kayumba A, Esposito F, Popescu RA, García-Gómez J, Heyman L, Smit T, Krendyukov A, Mathieson N, Cooksley T, Anderson R, Klastersky J. Leon Rapoport B, et al. Among authors: krendyukov a. Support Care Cancer. 2023 Oct 13;31(12):628. doi: 10.1007/s00520-023-08071-0. Support Care Cancer. 2023. PMID: 37828258 Free PMC article.
Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study.
Rapoport BL, Aapro M, Paesmans M, van Eeden R, Smit T, Krendyukov A, Klastersky J. Rapoport BL, et al. Among authors: krendyukov a. BMC Cancer. 2018 Sep 24;18(1):917. doi: 10.1186/s12885-018-4838-z. BMC Cancer. 2018. PMID: 30249215 Free PMC article.
Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
McBride A, Krendyukov A, Mathieson N, Campbell K, Balu S, Natek M, MacDonald K, Abraham I. McBride A, et al. Among authors: krendyukov a. J Med Econ. 2020 Jan;23(1):28-36. doi: 10.1080/13696998.2019.1658591. Epub 2019 Sep 3. J Med Econ. 2020. PMID: 31433700 Free article.
Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.
Bokemeyer C, Gascón P, Aapro M, Ludwig H, Boccadoro M, Denhaerynck K, Gorray M, Krendyukov A, Abraham I, MacDonald K. Bokemeyer C, et al. Among authors: krendyukov a. Support Care Cancer. 2017 Jun;25(6):1819-1828. doi: 10.1007/s00520-017-3572-4. Epub 2017 Jan 22. Support Care Cancer. 2017. PMID: 28111718 Free PMC article.
Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.
Ludwig H, Gascón P, Bokemeyer C, Aapro M, Boccadoro M, Denhaerynck K, Krendyukov A, MacDonald K, Abraham I. Ludwig H, et al. Among authors: krendyukov a. Support Care Cancer. 2019 Jun;27(6):2301-2312. doi: 10.1007/s00520-018-4513-6. Epub 2018 Oct 20. Support Care Cancer. 2019. PMID: 30343410
43 results